These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 26062020)

  • 21. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
    Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
    Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
    Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
    Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
    Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
    San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
    Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
    Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
    Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria.
    Schuurmans MM; Hoffmann F; Lindberg RL; Meyer UA
    Hepatology; 2001 May; 33(5):1217-22. PubMed ID: 11343251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute intermittent porphyria in childhood: a population-based study.
    Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
    Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
    Jiang L; Berraondo P; Jericó D; Guey LT; Sampedro A; Frassetto A; Benenato KE; Burke K; Santamaría E; Alegre M; Pejenaute Á; Kalariya M; Butcher W; Park JS; Zhu X; Sabnis S; Kumarasinghe ES; Salerno T; Kenney M; Lukacs CM; Ávila MA; Martini PGV; Fontanellas A
    Nat Med; 2018 Dec; 24(12):1899-1909. PubMed ID: 30297912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.
    Anderson KE; Alvares AP; Sassa S; Kappas A
    Clin Pharmacol Ther; 1976 Jan; 19(1):47-54. PubMed ID: 1245093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.
    Linenberger M; Fertrin KY
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):400-410. PubMed ID: 33275677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Glucose effect" and rate limiting function of uroporphyrinogen synthase on porphyrin metabolism in hepatocyte culture: relationship with human acute hepatic porphyrias.
    Doss M; Sixel-Dietrich F; Verspohl F
    J Clin Chem Clin Biochem; 1985 Sep; 23(9):505-13. PubMed ID: 4067519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor.
    Barreda-Sánchez M; Buendía-Martínez J; Glover-López G; Carazo-Díaz C; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Rodriguez-Peña L; Serrano-Antón AT; Gil-Ferrer R; Martínez-Romero MDC; Carbonell-Meseguer P; Guillén-Navarro E
    Orphanet J Rare Dis; 2019 Feb; 14(1):59. PubMed ID: 30808393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
    Ulbrichova D; Hrdinka M; Saudek V; Martasek P
    FEBS J; 2009 Apr; 276(7):2106-15. PubMed ID: 19292878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
    Aarsand AK; Petersen PH; Sandberg S
    Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.